寻求批准：寻常型天疱疮的现有及未来疗法
Seeking approval: present and future therapies for pemphigus vulgaris.
作者信息
Mao Xuming, Payne Aimee S
机构信息
University of Pennsylvania, Department of Dermatology, 217A Clinical Research Building, 415 Curie Boulevard, Philadelphia, PA 19104, USA.
出版信息
Curr Opin Investig Drugs. 2008 May;9(5):497-504.
Abstract
Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes. Despite the potentially fatal prognosis, there are currently no FDA-approved treatments specifically for pemphigus. In 2006, the FDA designated orphan drug status to mycophenolate mofetil for the treatment of pemphigus vulgaris, indicating both federal and commercial interest in developing therapies for this devastating disease. This review focuses on pemphigus therapies that are currently in preclinical or clinical trials, as well as potential novel therapies based on recent advances in the understanding of the pathophysiology of this disease.
摘要
寻常型天疱疮是一种皮肤和黏膜的自身免疫性水疱病。尽管预后可能致命，但目前尚无美国食品药品监督管理局（FDA）批准的专门用于治疗天疱疮的疗法。2006年，FDA指定霉酚酸酯用于治疗寻常型天疱疮的孤儿药地位，这表明联邦政府和商业机构都有兴趣开发针对这种毁灭性疾病的治疗方法。本综述重点关注目前处于临床前或临床试验阶段的天疱疮治疗方法，以及基于对该疾病病理生理学理解的最新进展的潜在新型疗法。
相似文献
1
Seeking approval: present and future therapies for pemphigus vulgaris.寻求批准：寻常型天疱疮的现有及未来疗法
Curr Opin Investig Drugs. 2008 May;9(5):497-504.
2
The actual management of pemphigus.天疱疮的实际管理。
G Ital Dermatol Venereol. 2010 Oct;145(5):689-702.
3
Treatment strategies for pemphigus vulgaris in Japan.日本寻常型天疱疮的治疗策略。
Expert Opin Pharmacother. 2008 Jun;9(9):1519-30. doi: 10.1517/14656566.9.9.1519.
4
Treatment of pemphigus vulgaris: current and emerging options.寻常型天疱疮的治疗：当前及新出现的选择
Am J Clin Dermatol. 2005;6(5):327-42. doi: 10.2165/00128071-200506050-00006.
5
Pemphigus vulgaris: approach to treatment.寻常型天疱疮：治疗方法
Eur J Dermatol. 2015 Apr;25(2):103-13. doi: 10.1684/ejd.2014.2483.
6
Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.利妥昔单抗联合霉酚酸酯治疗难治性寻常型天疱疮
An Bras Dermatol. 2014 Nov-Dec;89(6):980-4. doi: 10.1590/abd1806-4841.20143128.
7
Diagnosis and treatment of pemphigus.天疱疮的诊断与治疗。
Immunotherapy. 2012 Jul;4(7):735-45. doi: 10.2217/imt.12.67.
8
Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.用吗替麦考酚酯成功治疗四例寻常型天疱疮日本患者。
Eur J Dermatol. 2010 Jul-Aug;20(4):472-5. doi: 10.1684/ejd.2010.0966. Epub 2010 Apr 20.
9
Novel Therapies for Pemphigus Vulgaris.天疱疮的新型治疗方法。
Am J Clin Dermatol. 2020 Dec;21(6):765-782. doi: 10.1007/s40257-020-00544-w.
10
Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome).副肿瘤天疱疮（副肿瘤性自身免疫多器官综合征）的当前治疗策略。
Dermatol Clin. 2011 Oct;29(4):607-12. doi: 10.1016/j.det.2011.06.016. Epub 2011 Aug 15.
引用本文的文献
1
Possible therapeutic target MKK3 in blister formation in pemphigus.天疱疮水疱形成中可能的治疗靶点MKK3
Arch Dermatol Res. 2024 Jun 8;316(7):352. doi: 10.1007/s00403-024-03136-4.
2
What protein kinases are crucial for acantholysis and blister formation in pemphigus vulgaris? A systematic review.哪些蛋白激酶对寻常型天疱疮的棘层松解和水疱形成至关重要？一项系统评价。
J Cell Physiol. 2022 Jul;237(7):2825-2837. doi: 10.1002/jcp.30784. Epub 2022 May 26.
3
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.深入皮肤问题：靶向治疗皮肤自身免疫性疾病。
Yale J Biol Med. 2020 Mar 27;93(1):197-206. eCollection 2020 Mar.
4
Pemphigus: Current and Future Therapeutic Strategies.天疱疮：当前和未来的治疗策略。
Front Immunol. 2019 Jun 25;10:1418. doi: 10.3389/fimmu.2019.01418. eCollection 2019.
5
p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity.天疱疮中的p38丝裂原活化蛋白激酶信号传导：对皮肤自身免疫的影响
Autoimmune Dis. 2013;2013:728529. doi: 10.1155/2013/728529. Epub 2013 Jul 10.
6
Enrichment of total serum IgG4 in patients with pemphigus.天疱疮患者血清总 IgG4 的富集。
Br J Dermatol. 2012 Dec;167(6):1245-53. doi: 10.1111/j.1365-2133.2012.11144.x. Epub 2012 Sep 27.
本文引用的文献
1
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.天疱疮疾病、终点指标及治疗反应定义的共识声明。
J Am Acad Dermatol. 2008 Jun;58(6):1043-6. doi: 10.1016/j.jaad.2008.01.012. Epub 2008 Mar 14.
2
Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.氨苯砜作为寻常型天疱疮维持期糖皮质激素节省剂的多中心随机、双盲、安慰剂对照临床试验。
Arch Dermatol. 2008 Jan;144(1):25-32. doi: 10.1001/archderm.144.1.25.
3
Differential coupling of M1 muscarinic and alpha7 nicotinic receptors to inhibition of pemphigus acantholysis.M1毒蕈碱受体和α7烟碱受体对天疱疮棘层松解抑制作用的差异偶联
J Biol Chem. 2008 Feb 8;283(6):3401-3408. doi: 10.1074/jbc.M704956200. Epub 2007 Dec 11.
4
Induction of p38MAPK and HSP27 phosphorylation in pemphigus patient skin.天疱疮患者皮肤中p38丝裂原活化蛋白激酶（p38MAPK）和热休克蛋白27（HSP27）磷酸化的诱导作用
J Invest Dermatol. 2008 Mar;128(3):738-40. doi: 10.1038/sj.jid.5701080. Epub 2007 Oct 11.
5
A single cycle of rituximab for the treatment of severe pemphigus.利妥昔单抗单周期治疗重度天疱疮。
N Engl J Med. 2007 Aug 9;357(6):545-52. doi: 10.1056/NEJMoa067752.
6
Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.寻常型天疱疮四种治疗方案的随机对照开放标签试验
J Am Acad Dermatol. 2007 Oct;57(4):622-8. doi: 10.1016/j.jaad.2007.05.024. Epub 2007 Jun 21.
7
Beyond steric hindrance: the role of adhesion signaling pathways in the pathogenesis of pemphigus.超越空间位阻：黏附信号通路在天疱疮发病机制中的作用
J Dermatol Sci. 2007 Oct;48(1):1-14. doi: 10.1016/j.jdermsci.2007.05.005. Epub 2007 Jun 18.
8
Novel strategies for inhibition of the p38 MAPK pathway.抑制p38丝裂原活化蛋白激酶途径的新策略。
Trends Pharmacol Sci. 2007 Jun;28(6):286-95. doi: 10.1016/j.tips.2007.04.008. Epub 2007 May 7.
9
Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.环磷酰胺、硫唑嘌呤和环孢素（环孢菌素）作为寻常型天疱疮辅助药物的疗效和安全性。
Am J Clin Dermatol. 2007;8(2):85-92. doi: 10.2165/00128071-200708020-00004.
10
Targeting pemphigus autoantibodies through their heavy-chain variable region genes.通过天疱疮自身抗体的重链可变区基因对其进行靶向治疗。
J Invest Dermatol. 2007 Jul;127(7):1681-91. doi: 10.1038/sj.jid.5700790. Epub 2007 Mar 29.
Zotero 插件